Skip to main content
. 2025 Aug 8;16:1621887. doi: 10.3389/fpsyt.2025.1621887

Figure 1.

Pathways targeted by new antidepressants include NMDA receptor antagonism by Ketamine and Esketamine, Sigma-1 receptor agonism by Dextromethorphan, GABA-A receptor modulation by Brexanolone and Zuranolone, and Kappa receptor antagonism by Esmethadone, all affecting BDNF.

Mechanisms of action of novel antidepressants discussed in this review, including NMDA receptor modulation, GABA-A receptor potentiation, and multimodal serotonergic activity.